細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體
Monoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)
CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1
- 編號(hào)UMAA788Ra22
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 來(lái)源單抗制備
- 宿主小鼠
- 效價(jià)(克隆號(hào))E2
- Ig亞型 IgG1 Kappa
- 純化方式蛋白A + 蛋白G親和純化
- 標(biāo)記物無(wú)標(biāo)記物
- 免疫原 RPA788Ra01-細(xì)胞程序性死亡蛋白1配體1(PDL1)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度1mg/mL
- 且適物種-
- 應(yīng)用WB
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見(jiàn)流式抗體。 - 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 350 ¥ 817 ¥ 1167 ¥ 2918 ¥ 11670
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Western Blot; Sample: Lane1: Rat Serum; Lane2: Rat Skeletal muscle lysate Primary Ab: 2μg/ml Mouse Anti-Rat PDCD1LG1 Antibody Second Ab: 0.2μg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody (Catalog: SAA544Mu19)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)PDL1的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別PDL1。
用法
Western blotting: 0.5-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過(guò)兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽(yáng)性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA788Ra01 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA788Ra01 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)多克隆抗體 | WB |
| ULAA788Ra41 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)多克隆抗體(藻紅素標(biāo)記) | WB |
| ULAA788Ra71 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)多克隆抗體(生物素標(biāo)記) | WB |
| UMAA788Ra24 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB; IHC; ICC; IP. |
| UMAA788Ra22 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB |
| UMAA788Ra23 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB; IHC; ICC; IP. |
| UMAA788Ra21 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB |
| USEA788Ra | 細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA788Ra | 細(xì)胞程序性死亡蛋白1配體1(PDL1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Chinese Journal of Cancer | Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications [NCBI: PMC3937742] |
| Leukemia.? | High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. [Pubmed:24732592] |
| Diabetes?Metab Res Rev. | PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile [Pubmed:24816853] |
| Lancet Haematol | Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study [PubMed: 26686046] |
| Eur J Cancer.? | High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. [Pubmed:27039170] |
| Journal of Cancer Research and Clinical Oncology | Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer [article:10.1007] |
| Journal of Hematology & Oncology | PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma [pubmed:27737703] |
| Lung Cancer. | High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. [pubmed:28212990] |
| Oncotarget | Soluble?programmed?death-ligand?1?(sPDL1) and?neutrophil-to-lymphocyte?ratio?(NLR)?predictssurvival?in?advanced?biliary?tract?cancer?patients?treated?with palliative chemotherapy. [pubmed:27780932] |
| Oncotarget | High?post-treatment?serum?levels?of?soluble?programmed?cell?death?ligand?1?predict?earlyrelapse?and?poor?prognosis?in?extranodal?NK/T?cell?lymphoma patients. [pubmed:27105512] |
| Oncotarget.? | Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma [pubmed:27566569] |
| Cancer Immunol Immunother. | Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. [pubmed:28349165] |
| Leukemia | Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients [leu2016385a] |
| Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. [pubmed:28207525] |
| Allergology International? | Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients [pubmed:27617656] |
| Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy [PMC5319514] |
| American Journal of Respiratory and Critical Care Medicine | Soluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM) [Pdf:10.1164] |
| Clinical Lung Cancer | Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer [Pubmed:29859759] |
| Journal of Rheumatology | Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis [Pubmed:29419471] |
| Translational?Oncology | High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma [Pubmed:29698935] |
| Immunology?Letters | Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals [Pubmed: 30236481] |
| Journal of?Cancer?Research?and?Clinical?Oncology | Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma [Pubmed: 30267213] |
| Annals?of?Surgical?Oncology | Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between?… [Pubmed: 30565045] |
| American Journal of Reproductive Immunology | Identification of programmed cell death 1 and its ligand in the testicular tissue of mice [Pubmed: 30578744] |
| PLoS?One | Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated?… [Pubmed: 30807610] |
| Endocrine Connections | Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer [Pubmed: 31252406] |
| Scientific Reports | Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer [Pubmed: 31366979] |
| Critical Reviews in Oncology / Hematology | The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer [Pubmed: 31675543] |
| PLoS One | Clinical implications of APOBEC3A and 3B expression in patients with breast cancer [Pubmed: 32176735] |
| Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study [Pubmed: 32085544] |
| Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma [Pubmed: 32054467] | |
| LIVER INTERNATIONAL | The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer [Pubmed: 32780918] |
| CANCER IMMUNOLOGY IMMUNOTHERAPY | Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients [Pubmed: 32577816] |
| Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure [Pubmed: 32443313] | |
| Cancer Immunol Immunother | The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte [33688997] |
| Acta Biochim Biophys Sin | Prognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management [34180502] |
| EMBO J | Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology [34825707] |
| Mol Pharm | A Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors [34910492] |
| Mol Hum Reprod | Macrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis [Pubmed:35404426] |
| Journal of Nanobiotechnology | Microbial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape [Pubmed:35705974] |
| Medicina | Assessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A?… [Pubmed:35208526] |
留言咨詢
